Multiple Myeloma Day

Multiple Myeloma Day

Mar 29, 2019

multiple myeloma day
Multiple Myeloma Day

Multiple Myeloma is relatively a rare disease. It accounts for approximately 1% of all cancers and 10% of all blood and bone marrow cancers. For more information on  Multiple Myeloma.

Downloads

Article in PDF

Recent Articles
  1. Gilead’s TRODELVY Shows PFS Benefit in 1L Metastatic TNBC; Otsuka’s Sibeprenlimab Gets FDA Priori...
  2. AstraZeneca’s Imfinzi Shows Positive Results; Novartis Announces Results of Tislelizumab; FDA Gra...
  3. The Changing Landscape of Multiple Myeloma Therapies Market
  4. EMA to review Cidara Therapeutics’ Rezafungin; EU Approves Gilead Sciences’ Sunlenca; FDA Approve...
  5. DARZALEX FASPRO Quadruplet Regimen Demonstrates Striking Advancements in Treatment Outcomes for N...
bispecific-antibodies-for-multiple-myeloma-treatment
Articles

A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray

pharma-news-for-gilead -otsuka-liquidia
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Gilead’s TRODELVY Shows PFS Benefit in 1L Metastatic TNBC; Otsuka’s Sibeprenlimab Gets FDA Priority Review for IgA Nephropathy; Liquidia Wins FDA Nod for YUTREPIA in PAH and PH-ILD; GSK’s BLENREP Combos Get CHMP Backing in Myeloma; Relief Therapeutics Receives FDA Rare Pediatric Disease Tag for RLF-TD011

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Abeona Secures FDA Nod for ZEVASKYN, the First Gene Therapy for RDEB; AbbVie Gains FDA Approval for RINVOQ in Giant Cell Arteritis; Lantern Pharma Advances LP-184 with IND Clearance for TNBC Trial; Ichnos Glenmark Earns FDA Fast Track for ISB 2001 in Multiple Myeloma; Rezolute Wins Breakthrough Therapy Designation for Ersodetug in Tumor-Induced Hypoglycemia

Multiple Myeloma
Multiple MYELOMA drugs Market.
Multiple Myeloma Market
Multiple Myeloma Pipeline
RBC
red blood cells
loader
loader